Article Sidebar

Submitted
Dec 5, 2024
Published
Dec 5, 2024
Download
PDF
Statistic
Read Counter : 21 Download : 7

Main Article Content

Abstract

The purpose of the present investigation is to formulate and invitro evaluation of mucoadhesive buccal tablets of Losartan potassium using natural polymer. Losartan potassium is an angiotensin II receptor (type AT1 ) antagonist. Losartan is an orally active agent that undergoes substantial first pass metabolism by cytochrome P450 enzyme. It is converted into carboxylic acid metabolites. The aim of the present study was to design mucoadhesive buccal tablets to release the drug unidirectionally in buccal cavity for extended period of time in order to avoid first pass metabolism for improvement in bioavailability to reduce the dosing frequency and to improve patient compliance. Tablets of Losartan potassium were prepared by direct compression method using natural polymers sodium alginate, xanthan gum and guar gum. Preformulation studies like FTIR were done and postformulation studies like mucoadhesive force, mucoadhesive strength and swelling index were done and compared with different natural polymer.

Keywords

Mucoadhesive Buccal Tablets Losartan Potassium Natural Polymers First Pass Metabolism in vitro evaluation

Article Details

How to Cite
S. Kavibharathi, Deepthi K.C, S. Chandra, & N. Senthil Kumar. (2024). Formulation and in vitro evaluation of mucoadhesive buccal tablets of losartan potassium using natural polymer. International Journal of Research in Pharmacology & Pharmacotherapeutics, 13(4), 665-674. Retrieved from https://ijrpp.com/ijrpp/article/view/601
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. 1. Welling, P. G., Barbhaiya, R. H. Effects of food on the pharmacokinetics of Irbesartan/Hydrochlorothiazide combination Tablet. J.Pharm. Sci., 1982, 71(6):32.
  2. 2. Pandit JK, Vemuri NM, Wahi SP, Jayachandra Babu R. Mucosal Dosage Form of Ephedrine Hydrochloride using Gantrez-AN 139. Eastern Pharmacist 1993;36:169-170.
  3. 3. Gupta A, Garg S, Khar RK. Mucoadhesive Buccal Drug Delivery System: A Review. Indian Drugs 1992;29(13):586-93.Harris D, Robinson JR. Drug Delivery via Mucous Membrane of the Oral Cavity. J Pharm Sci 1992;81:1-10.
  4. 4. Wong FC, Yuen KH, Peh KK. Formulation and Evaluation of Controlled Release Eudragit Bucccal Patches. Int J Pharm 1999;178:11-2.
  5. 5. Ponchel G, Irache J. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Delivery. 1998;34:191-219.
  6. 6. S. J.Hwang, H. Park and K. Park, “Gastric Retentive Drug-Delivery Systems”, Crit. Rev. Ther. Drug Carrier Syst. 1998, 15 (3), 243–284.
  7. 7. L. Whitehead, J. T. Fell and J H Collett, “Development of a Gastroretentive Dosage Form”, Eur. J. Pharma. Sci., 1996, 4 (1),182.
  8. 8. P. Mojaverian, P. H. Vlasses, P. E. Kellner and M. . Rocci, “Effects of gender, posture and age on gastric residence time of an indigestible solid: pharmaceutical considerations”, Pharm. Res., 1988, 10, 639–644.
  9. 9. Singh B, Ahuja N. Response surface optimization of drug delivery system. In: Jain NK, ed. Progress in Controlled and Novel Drug Delivery Systems. New Delhi, India: CBS Publishers and Distributors; 2004, 20, 240.
  10. 10. Yamagar M, Kadam V, Hirlekar R. Design and evaluation of buccoadhesivedrug delivery system of metoprolol tartrate. Int J Pharm Tech Res. 2010;2(1): 453-462.
  11. 11. Vasir JK, Tambwekar K, Garg S.Bioadhesive microspheres as a controlled drug delivery. J Control Release 1998;55:143-52.
  12. 12. Semalty A., Bhojwani M., Bhatt G., Gupta G., Shrivastav A. Design and evaluation of mucoadhessive buccal films of diltiazem hydrochloride. Indian J of PharmaceuticalSciences, 2005;67(5):548-552.
  13. 13. Guda A, Gudas GK, Bingi B, Debnath S, Rajesham VV. Design and evaluation of controlled release mucoadhesive buccal tablets of lisinopril. Int J Curr Pharm Res. 2010; 2(4): 24-27.
  14. 14. K.P.R. Chowdary, B.Suresh, B.Sangeeta and G.Kamalakara Reddy “Design and Evaluation of Diltiazem Mucoadhesive Tablets for Oral Controlled Release”of Saudi Pharmaceutical Journal, Vol 11, No. 4,october 2003.
  15. 15. Shukla, S., Prasad, S., Sharma, E.K., The Opportunities for Indian Pharma., Out Look , 2002, Oct.-13, 41-49. 5.Nagai, T. and Machida, Y., Mucosal Adhesive Dosage Forms, Pharm. Int., 1985, 196-200.
  16. 16. Bodde, H.E., De Vries, M.E.and Junginger, H.E., Mucoadhesive Polymers for the Buccal Delivery of Peptides, Structure-Adhesiveness Relationships, J. Control. Rel., 1990, 13:225-231.
  17. 17. Mathiowitz, E., Chickering, D., Jacob, J. S.and Santos, C., In; Mathiowitz, E., Eds, Encyclopedia of Controlled Drug Delivery, Vol. 1, John Willey & Sons, New York, 1999, 9- 44.
  18. 18. Squier, C.A.and Wertz, P.W., Structure and Function of the Oral Mucosa and Implications for Drug Delivery, in, M.J. Rathbone, Eds; Oral Mucosal Drug Delivery, 1996, Marcel Dekker, Inc., New York,1-26.
  19. 19. Bhaskar U., Patil R., Birajdar R., Mysore S., Bilagi S., Audurti D. Formulation and In-Vitro Evaluation of Mucoadhesive Buccal Tablets of Furosemide. World J of Pharmacy and Pharmaceutical Sciences, 2012; 1(3):1041-1063.